CSTLCastle Biosciences, Inc.
$33.72+47% 1Y
$33.72
$18.1552 weeks$43.04
CSTL in its own filings
Nothing in CSTL's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
130
Events found in the filings · across 880 filings · the record starts in 2019
- Hard flags
- none
Hard flags
- Most recent filing
- Jul 30, 2026
Most recent filing · Form 10-Q
- Record starts
- Jun 10, 2019
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 2, 2026
- SEC comment-letter activity13 occurrences
- 2024-04-12
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Jul 30, 2026Castle Biosciences Reports Second Quarter 2026 Results.Earnings release · press release
- May 6, 2026Castle Biosciences Reports First Quarter 2026 Results.Earnings release · press release
- Feb 26, 2026Castle Biosciences Reports Fourth Quarter and Full–Year 2025 Results.Earnings release · press release
- Jan 13, 2026©2026 Castle Biosciences 1 Empowering people, informing care decisions Preliminary Unaudited Fourth Quarter and Year-End Results 2025 January 2026.Earnings release · press release
- Nov 3, 2025Castle Biosciences Reports Third Quarter 2025 Results.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
Diagnostics & Research
Ranks #11 of 21 by RyuScore